Dick Bagley
President & Chief Operating Officer
ZIOPHARM Oncology, Inc.

Murray Brennan, MD
Chairman of Surgery, Memorial Sloan-Kettering Cancer Center

Dr. Brennan has been chairman of Memorial Sloan-Kettering's Department of Surgery since 1985. He is widely regarded as being one of the best and most famous surgeons in the world. Dr. Brennan has lectured and been visiting professor throughout the world and has authored more than 800 scientific papers. He has served as director of the American Board of Surgery, chairman of the American College of Surgeons Commission on Cancer, president of the Society of Surgical Oncology, and president of the American Surgical Association, the oldest and most prestigious surgical association in the United States. Dr. Brennan is currently vice president of the American College of Surgeons, and a member of the National Academy of Sciences. He is the recipient of numerous honors and medals for his leadership of surgery and oncology worldwide.

James A. Cannon
Chief Financial Officer and Vice Chairman, BBDO

James (Jim) Cannon is vice chairman, chief financial officer and a member of the board of directors of BBDO Worldwide. In this capacity, he oversees the financial management of BBDO operations in 77 countries. Jim joined BBDO in 1967, was promoted to chief financial officer of the agency in 1984, and was elected to its board of directors one year later. An integral member of the team that formed Omnicom via a unique three-agency merger of BBDO, DDB and Needham Harper & Steers, Jim became comptroller of the new group (NYSE: OMC) and a member of its board of directors in 1986, a position he held through 2002. In 1987, he was appointed director of financial operations of the Omnicom Group, serving in this capacity until early 1989 when he rejoined BBDO Worldwide as executive vice president and chief financial officer. His return was concurrent with that of Allen Rosenshine who became chairman and chief executive officer of BBDO after heading Omnicom. Jim was promoted to vice chairman of the agency in 1990. Jim is a graduate of Pace University and served in the US Marine Corps.

Senator Wyche Fowler, Jr., JD
former US Senator and Ambassador to Saudi Arabia.

Senator Wyche Fowler, Jr. served for 16 years in the United States Congress. In the US Senate, he served as assistant floor leader, helping mould a bipartisan consensus for major public policy issues. Senator Fowler was a member of the Senate Appropriations, Budget, Energy and Agriculture Committees. First elected to the US House of Representatives, he was a member of the Ways and Means and Foreign Affairs Committees, as well as the Select Committee on Intelligence. President Clinton appointed Senator Fowler US Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. On his return, the FBI awarded him its highest civilian honor, The Jefferson Cup, for his assistance in combating terrorism and for helping solve terrorism crimes against the US military in Saudi Arabia. He was named Lion of Judah by the State of Israel for successfully freeing Soviet Jew Yakov Gluzman. Senator Fowler is now engaged in an international business and law practice, and also serves as chairman of the board of the Middle East Institute, a non-profit foundation in Washington, DC.

Gary S. Fragin
Managing partner of Fragin Asset Management, LP; former Director of Trading, Oppenheimer & Co.; former General Partner and Chief Administrative/Operating Officer, Steinhardt Organization

Gary S. Fragin has more than 30 years of experience on Wall Street. He is currently managing partner of Fragin Asset Management, LP. Mr. Fragin was the general partner and chief administrative/operating officer of Steinhardt Organization, one of the largest and most successful hedge funds in existence at that time. Prior to that, Mr. Fragin was a partner, director of trading, and member of the Management Committee and Executive Committee at Oppenheimer and Co. He holds a BS degree from Vanderbilt University, and an MBA from Columbia University.

Jonathan Lewis, MD, PhD
Chief Executive Officer and Executive Chairman,
ZIOPHARM Oncology, Inc.

Timothy McInerney
Managing Director of Paramount BioCapital, Inc.

Since 1992, Mr. McInerney has been a Managing Director of Paramount BioCapital, Inc. where he oversees the overall distribution of Paramount's private equity product. Prior to 1992, Mr. McInerney was a research analyst focusing on the biotechnology industry at Ladenburg, Thalman & Co. Prior to that, Mr. McInerney held equity sales positions at Bear Sterns & Co. and Shearson Lehman Brothers, Inc. Mr. McInerney also has worked in sales and marketing for Bristol-Myers Squibb. He received his B.S. in pharmacy from St. John's University at New York. He also completed a post-graduate residency at the New York University Medical Center in drug information systems.

Michael Weiser, MD, PhD
Director of Research, Paramount Capital Asset Management, Inc.

Michael Weiser is a director of the Company and has served on ZIOPHARM's board of directors since ZIOPHARM's inception. Dr. Weiser is the Director of Research of Paramount BioCapital. In addition to serving on the boards of directors of several privately-held companies, Dr. Weiser currently serves on the board of directors of Manhattan Pharmaceuticals, Inc., VioQuest Pharmaceuticals, Inc., Hana BioSciences, Inc. and Chelsea Therapeutics, Inc., all publicly-traded biotechnology companies.